<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>319</serviceExecutionTime><Drug id="52765"><DrugName>AZD-6538</DrugName><DrugSynonyms><Name><Value>AZD-6538</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="14190">AstraZeneca plc</CompanyOriginator><CompaniesSecondary><Company id="14190">AstraZeneca plc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="52765" type="Drug"><TargetEntity id="390471" type="siDrug">AZD-6538</TargetEntity></SourceEntity><SourceEntity id="14190" type="Company"><TargetEntity id="4295894341" type="organizationId">AstraZeneca PLC</TargetEntity></SourceEntity><SourceEntity id="1243" type="ciIndication"><TargetEntity id="K21" type="ICD10"></TargetEntity><TargetEntity id="530.81" type="ICD9"></TargetEntity><TargetEntity id="10017885" type="MEDDRA"></TargetEntity><TargetEntity id="D005764" type="MeSH"></TargetEntity><TargetEntity id="-837084427" type="omicsDisease"></TargetEntity><TargetEntity id="389" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1295" type="ciIndication"><TargetEntity id="10029223" type="MEDDRA"></TargetEntity><TargetEntity id="D009437" type="MeSH"></TargetEntity><TargetEntity id="-533466818" type="omicsDisease"></TargetEntity><TargetEntity id="14" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="1243">Gastroesophageal reflux</Indication><Indication id="1295">Neuropathic pain</Indication></IndicationsSecondary><ActionsSecondary><Action id="1332">Gastrointestinal system agent</Action><Action id="59620">Unspecified drug target</Action><Action id="2946">Analgesic</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-11-17T16:48:29.000Z</LastModificationDate><ChangeDateLast>2007-08-13T16:08:28.000Z</ChangeDateLast><AddedDate>2005-02-07T14:54:47.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="14190" linkType="Company"&gt;AstraZeneca&lt;/ulink&gt;  was investigating  AZD-6538  for the potential treatment of neuropathic pain  [&lt;ulink linkID="582814" linkType="Reference"&gt;582814&lt;/ulink&gt;]. It had been selected as a clinical candidate by January 2005 [&lt;ulink linkID="582814" linkType="Reference"&gt;582814&lt;/ulink&gt;].  In February 2007, preclinical studies were ongoing. At that time, the specific mechanism of action was undisclosed  [&lt;ulink linkID="762824" linkType="Reference"&gt;762824&lt;/ulink&gt;]. By July 2007, development of this drug had been discontinued [&lt;ulink linkID="816181" linkType="Reference"&gt;816181&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;AstraZeneca had previously  been investigating AZD-6538 for the potential treatment of gastroesophageal reflux disease (GERD) [&lt;ulink linkID="615253" linkType="Reference"&gt;615253&lt;/ulink&gt;]. By June 2006, however, the drug's development for  GERD had been discontinued [&lt;ulink linkID="673401" linkType="Reference"&gt;673401&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1243">Gastroesophageal reflux</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-06-08T00:00:00.000Z</StatusDate><Source id="673401" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-07-26T00:00:00.000Z</StatusDate><Source id="816181" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1243">Gastroesophageal reflux</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-07-28T00:00:00.000Z</StatusDate><Source id="615253" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-01-27T00:00:00.000Z</StatusDate><Source id="582814" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>